Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

Elanco Animal Health Cut to Equal-Weight From Overweight by Morgan Stanley Equity Lifestyle Raised to Overweight From Equal-Weight by Wells Fargo Five Below Cut to Underweight From Neutral by JP ...

Because this plan is a short plan based on a test of resistance it is referred to as a Short Resistance Plan. Check the time stamp on this data. Updated AI-Generated Signals for Halozyme Therapeutics ...

Fintel reports that on September 19, 2024, JP Morgan downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

Halozyme Therapeutics (HALO) stock drops after J.P. Morgan downgrade, but analyst raises price target on Enhanze drug ...

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk ...

Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $61.93 which represents a decrease of $-0.98 or -1.56% from the prior close of $62.91. The stock opened at $62.91 and touched ...

BOSTON, Sept. 18, 2024 /PRNewswire/ -- Below is the August 2024 Monthly Update for the Liberty All-Star Growth Fund, Inc.

Kaskela Law LLC announces that it is investigating Halozyme Therapeutics, Inc. ("Halozyme") on behalf of the company's shareholders. The investigation seeks to determine whether Halozyme and/or the ...